Member access

4-Traders Homepage  >  Shares  >  Toronto Stock Exchange  >  Transition Therapeutics Inc    TTH   CA8937162094

 SummaryChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
01/26/2015 01/27/2015 01/28/2015 01/29/2015 01/30/2015 Date
8.6 8.35 8.58 8.58 8.91 Last
792 1770 1211 1221 937 Volume
+1.18% -2.91% +2.75% 0.00% +3.85% Change
Company
Transition Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapeutics for disease indications with large markets.It operates through research and development of therapeutic agents segment.The company's products include ELND005 for the treatment of alzheimer's... 
Sector
Pharmaceuticals
Calendar
02/11Earnings Release
More about the company
Chart TRANSITION THERAPEUTICS IN
Duration : Period :
Transition Therapeutics In Technical Analysis Chart | TTH | CA8937162094 | 4-Traders
Full-screen chart
Financials ( CAD)
Sales 2015 0,83 M
EBIT 2015 -39,2 M
Net income 2015 -27,7 M
Debt 2015 -
Yield 2015 -
Sales 2016 1,67 M
EBIT 2016 -24,1 M
Net income 2016 -12,8 M
Debt 2016 -
Yield 2016 -
PER 2015 -
PER 2016
Capi. / Sales 2015 378x
Capi. / Sales 2016 189x
Capitalization 315 M
More Financials
Latest news on TRANSITION THERAPEUTICS IN
2014 TRANSITION THERAPEUTICS : to Present at the Oppenheimer 25th Annual Healthcare C..
2014 TRANSITION THERAPEUTICS : Announces Results from ELND005 Clinical Study in Adult..
2014 TRANSITION THERAPEUTICS : Announces First Quarter Fiscal 2015 Financial Results
2014 TRANSITION THERAPEUTICS : to Hold Conference Call on First Quarter Fiscal 2015 F..
2014 TRANSITION THERAPEUTICS : Reports Findings from Bipolar Disorder Phase 2 Study
2014 TRANSITION THERAPEUTICS : Appoints Carl Damiani as Chief Operating Officer
2014 TRANSITION THERAPEUTICS : Enters Into a Private Placement with Investors to Rece..
2014 TRANSITION THERAPEUTICS : to Present at Jefferies 2014 Global Healthcare Confere..
More news
Sector news Biopharmaceuticals
08:04a Antibiotics firm Motif Bio to tap UK market for cash
01/31 JOHNSON & JOHNSON : Former FDA chief calls J&J misleading on Risperdal
01/30 SANOFI : 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana..
Plus d'actualités du secteur Biopharmaceuticals


Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF